A team led by Weizmann scientists has discovered that the protein PSME4 is produced by cancer cells to stop the immune system from attacking the tumor. Reducing PSME4 levels should potentially render tumors more vulnerable to immunotherapy. https://www.jns.org/israeli-researchers-unmask-how-cancer-camouflages-itself/ https://wis-wander.weizmann.ac.il/life-sciences/dumpster-diving-cancer-tissue-uncovers-immune-evasion-mechanism https://www.nature.com/articles/s43018-023-00557-4

Scientists at Jerusalem’s Hadassah hospital and Bar-Ilan University have developed HBI0101- a CAR-T therapy for multiple myeloma and amyloidosis, benefiting over 90% of patients in trials. Los Angeles-based Immix BioPharma will commercialize HBI0101. https://www.timesofisrael.com/after-demonstrating-57-remission-rate-israeli-immunotherapy-licensed-by-us-firm/ https://haematologica.org/article/view/haematol.2022.281628

Scientists at Israel’s Bar-Ilan University and Hadassah-University Medical Center, have developed a treatment for multiple myeloma. The patient’s T-cells are combined with a chimeric antigen receptor (CAR) molecule. In Phase 1 human trials at Hadassah. https://www.jpost.com/health-science/groundbreaking-made-in-israel-treatment-may-offer-cure-for-blood-cancer-664422

I have reported nearly 20 articles (see here) about Israeli scientists using immunotherapy to tackle cancer. Now Israel’s Cancer Research Fund and US Cancer Research Institute are partnering to decide which, of 160 Israeli research projects, could make the next … Continue reading →

Hebrew University of Jerusalem and Massachusetts Institute of Technology researchers have developed a protein “switch” that activates the immune system to attack cancer cells. They were able to distinguish cancer cells from healthy tissue by their DNA sequences. http://www.jpost.com/HEALTH-SCIENCE/Joint-Israeli-US-research-distinguishes-cancerous-cells-from-healthy-ones-508738 https://www.youtube.com/embed/vbWDuAev7Oo?rel=0

I reported in May that Israeli biotech Compugen discovered 4 new protein variants that stimulate the immune system into targeting cancer cells. Now tests have shown that CGEN-15001T will fight carcinomas, sarcomas, melanoma and haematological cancers. http://www.globes.co.il/serveen/globes/docview.asp?did=1000721404&fid=1725

Immune Checkpoint Inhibitors (ICIs) are successful in 40% of cancer patients but are invasive and time-consuming. Scientists at Israel’s Technion Institute have developed a tool that predicts the response based on the metabolic activity in the immune system cells. (See … Continue reading →

Israel’s Edity Therapeutics reprograms immune cells to recognize tumors that hide from the body’s regular immune system. Edity’s ED 007 cell therapy inflames these tumors, triggering the body’s own immune system to kill the cancer without risk of side effects … Continue reading →

Allocetra from Israel’s Enlivex (see here previously) saved many patients suffering from Covid-19 and sepsis. Clinical trials have now begun, using it to treat patients with advanced solid tumors. Allocetra reprograms immune system macrophages that cause cancer. https://www.jpost.com/jerusalem-report/article-713192 https://enlivex.com/investor-relations/#latest-news